The Spring Universal Infusion Set is compatible with most insulin pumps currently available on the market. It is a multi-level system of the latest innovations in materials and miniaturized technology, where each component enhances drug-delivery assurance, while striving to enrich the user experience.
The Spring Universal Infusion Set includes: a "Detach-Detect" mechanism which enhances insulin delivery assurance by alerting the user when the set is detached from the body; a hidden, auto-retractable 28-gauge needle with a trocar tip designed to reduce pain and scarring and to minimize cannula bending potential; and a 360 degrees -connector. By simplifying the insertion process with the one-touch button push, the user and the insurance companies benefit by increasing the odds of the proper insertion on the first try.
"This is a design innovation with real value to all stakeholders in diabetes management," said Zoe Myers, a long-time insulin pump user and D. Medical's Chief Commercial Officer. "Why is the Spring Universal attractive to every insulin pump user? Ask anyone with insulin-dependent diabetes: Would you rather not look at a needle and would you like the peace of mind of knowing that your insulin is being accurately delivered?"
Spring Zone Insulin Delivery System(i)
The proprietary Intellispring(TM) technology is at the heart of the Spring Zone Insulin Delivery System functionality. The pocket pump utilizes discrete pressure compensation, drawing the energy for insulin delivery from pressure created when insulin is loaded into the disposable Spring Exclusive infusion set and its spring mechanism is compressed. This ingenious mechanism, backed by the Total Line Control(TM) (TLC) safety check system, enables failsafe operation and exceptional reliability for continuously controlled and monitored insulin delivery.
Intellispring(TM) utilizes spring energy as the driving force for insulin delivery. The elimination of motor and gear train results in performance and cost advantages, increased service lifetime and reliability, and substantial weight reduction and size miniaturization. Other key innovative features of the Spring Zone insulin pump include superior blockage and detachment detection, environmental (pressure and temperature) adaptability and continuous insulin dose delivery check.
Spring Hybrid Patch Pump(i)
The innovative Intellispring(TM) technology that has been implemented in D. Medical's Traditional ADI Insulin Pump system has now been transformed into the world's first ever "hybrid" continuous insulin delivery system. It is hybrid because it can be worn either as a patch pump or a traditional, durable insulin pump.
"Our new Spring Hybrid Patch pump is revolutionary in a number of ways," said Hezkiah Tsoory, D. Medical's Chief Operating Officer. "Among the inherent technology features are the smallest increments in insulin therapy, the alert at any possible blockage event and the unique air bubble detection system. Going beyond that, this new product provides the user with the greatest lifestyle flexibility by allowing an alternative between having tube-free insulin delivery on a skin-patch, or using it as the smallest available traditional insulin pump. The flexibility of this IPX 8 water-tight device goes even further. Our pump can be used with or without a dedicated remote management tool. The remote unit also serves as a blood glucose meter. Finally, the Spring Hybrid Patch Pump offers a brand new industry level of environmental friendliness. The device is comprised of a multiple-use, long-lasting control element that clasps on a single-use drug reservoir. No electronic elements, soldering material or batteries are being disposed of; the only waste consists of a tiny plastic cartridge. This energy-saving, motorless system may run for about thirty days on a standard AAA battery."
(i) D. Medical's Spring Zone Insulin Delivery System and its Spring Hybrid Patch Pump are not approved for sale in the United States.
2011年6月6日星期一
In the five-center study to be published in Gastrointestinal Endoscopy
“…Performing an EUS-guided biopsy with the new histology needle was feasible and safe for histopathology diagnosis of intraintestinal and extraintestinal mass lesions in this consecutive series of patients,” said the study in its conclusion. “It offers the possibility of obtaining a core sample for histological evaluation in the majority of cases, with an overall diagnostic accuracy of over 85 percent.”
Dr. Julio Iglesias-Garcia, the lead investigator of the study and associate faculty member at the University Hospital of Santiago de Compostela, Spain, Gastroenterology department said, “the 19-gauge EchoTip ProCore needle by Cook Medical improves what is already an incredibly valuable diagnostic tool. The needle allows pathologists to sample a variety of lesions without compromising diagnostic accuracy, which could lead to earlier detection of GI malignancies.”
EUS is an established procedure for diagnosing GI cancers and determining the stage of their development. Most often, a very fine needle is used—but fine-needle aspiration (FNA) can have limited yield and sensitivity for certain kinds of tumors or in some anatomical locations and only procures a cytological sample.
The EchoTip ProCore needles circumvent this limitation by obtaining intact tissue samples2, allowing for a histological diagnosis rather than conventional cytological diagnosis based on individual cells. In addition to this advantage, the needles are designed to access difficult-to-reach tissue in areas of the GI tract such as the pancreatic head.
In the five-center study to be published in Gastrointestinal Endoscopy, the 19-gauge EchoTip ProCore retrieved adequate histological tissue samples in 89.5 percent of cases, and subsequent diagnosis proved accurate in more than 85 percent of total cases. The overall accuracy for detecting malignancy in EchoTip ProCore samples was greater than 92 percent. Moreover, 78 percent of the samples were collected with just one pass of the needle; in FNA, the recommended number of passes can be as high as seven. Researchers studied 109 patients with 114 intestinal lesions and/or peri-intestinal lymph nodes.
“Cook Medical’s EchoTip Ultra® line of needles are the world’s leading endoscopic ultrasound needles and are widely used for obtaining cytological and histological samples by EUS,” said Barry Slowey, global business unit leader for Cook Medical’s Endoscopy division, the industry’s only full-line supplier of endoscopic devices. “We’re proud to advance the technology in obtaining histological yields with the new EchoTip ProCore and further aid physicians in the early diagnosis and treatment of GI disorders.”
Dr. Julio Iglesias-Garcia, the lead investigator of the study and associate faculty member at the University Hospital of Santiago de Compostela, Spain, Gastroenterology department said, “the 19-gauge EchoTip ProCore needle by Cook Medical improves what is already an incredibly valuable diagnostic tool. The needle allows pathologists to sample a variety of lesions without compromising diagnostic accuracy, which could lead to earlier detection of GI malignancies.”
EUS is an established procedure for diagnosing GI cancers and determining the stage of their development. Most often, a very fine needle is used—but fine-needle aspiration (FNA) can have limited yield and sensitivity for certain kinds of tumors or in some anatomical locations and only procures a cytological sample.
The EchoTip ProCore needles circumvent this limitation by obtaining intact tissue samples2, allowing for a histological diagnosis rather than conventional cytological diagnosis based on individual cells. In addition to this advantage, the needles are designed to access difficult-to-reach tissue in areas of the GI tract such as the pancreatic head.
In the five-center study to be published in Gastrointestinal Endoscopy, the 19-gauge EchoTip ProCore retrieved adequate histological tissue samples in 89.5 percent of cases, and subsequent diagnosis proved accurate in more than 85 percent of total cases. The overall accuracy for detecting malignancy in EchoTip ProCore samples was greater than 92 percent. Moreover, 78 percent of the samples were collected with just one pass of the needle; in FNA, the recommended number of passes can be as high as seven. Researchers studied 109 patients with 114 intestinal lesions and/or peri-intestinal lymph nodes.
“Cook Medical’s EchoTip Ultra® line of needles are the world’s leading endoscopic ultrasound needles and are widely used for obtaining cytological and histological samples by EUS,” said Barry Slowey, global business unit leader for Cook Medical’s Endoscopy division, the industry’s only full-line supplier of endoscopic devices. “We’re proud to advance the technology in obtaining histological yields with the new EchoTip ProCore and further aid physicians in the early diagnosis and treatment of GI disorders.”
订阅：
博文 (Atom)